Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(-50.0%)
CAD 0.01
(-50.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.82 Million CAD | -12.9% |
| 2022 | -2.49 Million CAD | -84.46% |
| 2021 | -1.35 Million CAD | -159.65% |
| 2020 | -521.57 Thousand CAD | 76.38% |
| 2019 | -2.2 Million CAD | 21.33% |
| 2018 | -2.8 Million CAD | 28.58% |
| 2017 | -3.93 Million CAD | -180.81% |
| 2016 | 4.86 Million CAD | -3.79% |
| 2015 | 5.05 Million CAD | 104.06% |
| 2014 | 2.47 Million CAD | 51.46% |
| 2013 | 1.63 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -610.54 Thousand CAD | 8.24% |
| 2024 Q2 | -661.71 Thousand CAD | -8.38% |
| 2023 Q1 | -714.9 Thousand CAD | -68.24% |
| 2023 Q2 | -668.06 Thousand CAD | 6.55% |
| 2023 Q4 | -665.4 Thousand CAD | 13.8% |
| 2023 Q3 | -771.93 Thousand CAD | -15.55% |
| 2023 FY | -2.82 Million CAD | -12.9% |
| 2022 Q4 | -424.93 Thousand CAD | 17.58% |
| 2022 Q2 | -734.27 Thousand CAD | 8.37% |
| 2022 Q1 | -801.33 Thousand CAD | -278.09% |
| 2022 FY | -2.49 Million CAD | -84.46% |
| 2022 Q3 | -515.59 Thousand CAD | 29.78% |
| 2021 Q2 | -382.5 Thousand CAD | 22.97% |
| 2021 Q4 | -211.94 Thousand CAD | 19.49% |
| 2021 FY | -1.35 Million CAD | -159.65% |
| 2021 Q1 | -496.57 Thousand CAD | -185.97% |
| 2021 Q3 | -263.24 Thousand CAD | 31.18% |
| 2020 FY | -521.57 Thousand CAD | 76.38% |
| 2020 Q3 | -56.28 Thousand CAD | -14.11% |
| 2020 Q2 | -49.32 Thousand CAD | 79.64% |
| 2020 Q1 | -242.3 Thousand CAD | 30.52% |
| 2020 Q4 | -173.64 Thousand CAD | -208.5% |
| 2019 Q2 | -634.08 Thousand CAD | 13.43% |
| 2019 FY | -2.2 Million CAD | 21.33% |
| 2019 Q3 | -536.78 Thousand CAD | 15.35% |
| 2019 Q1 | -732.45 Thousand CAD | -9.32% |
| 2019 Q4 | -348.72 Thousand CAD | 35.03% |
| 2018 Q4 | -670 Thousand CAD | -2.64% |
| 2018 FY | -2.8 Million CAD | 28.58% |
| 2018 Q2 | -669.15 Thousand CAD | 17.9% |
| 2018 Q3 | -652.77 Thousand CAD | 2.45% |
| 2018 Q1 | -815.08 Thousand CAD | -28.09% |
| 2017 Q1 | 1.01 Million CAD | -14.63% |
| 2017 FY | -3.93 Million CAD | -180.81% |
| 2017 Q4 | -636.31 Thousand CAD | -165.85% |
| 2017 Q3 | 966.26 Thousand CAD | -29.9% |
| 2017 Q2 | 1.37 Million CAD | 35.92% |
| 2016 Q1 | 1.16 Million CAD | -15.02% |
| 2016 FY | 4.86 Million CAD | -3.79% |
| 2016 Q2 | 1.38 Million CAD | 18.89% |
| 2016 Q4 | 1.18 Million CAD | 6.0% |
| 2016 Q3 | 1.12 Million CAD | -19.26% |
| 2015 Q1 | 1.11 Million CAD | -18.31% |
| 2015 Q4 | 1.37 Million CAD | -2.8% |
| 2015 FY | 5.05 Million CAD | 104.06% |
| 2015 Q3 | 1.41 Million CAD | 22.4% |
| 2015 Q2 | 1.15 Million CAD | 3.67% |
| 2014 Q4 | 1.36 Million CAD | 372.77% |
| 2014 FY | 2.47 Million CAD | 51.46% |
| 2014 Q3 | -499.83 Thousand CAD | -231.52% |
| 2014 Q1 | 266.06 Thousand CAD | -19.72% |
| 2014 Q2 | 380.04 Thousand CAD | 42.84% |
| 2013 FY | 1.63 Million CAD | 0.0% |
| 2013 Q4 | 331.4 Thousand CAD | 33.63% |
| 2013 Q3 | 248 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| CanadaBis Capital Inc. | 4.67 Million CAD | 160.303% |
| Decibel Cannabis Company Inc. | 1.41 Million CAD | 299.737% |
| Delivra Health Brands Inc. | -710 Thousand CAD | -297.223% |
| Entourage Health Corp. | -21.37 Million CAD | 86.808% |
| Lifeist Wellness Inc. | -12.24 Million CAD | 76.977% |
| Cannara Biotech Inc. | 11.88 Million CAD | 123.724% |
| Medicure Inc. | -854 Thousand CAD | -230.244% |
| PharmaCielo Ltd. | -9.7 Million CAD | 70.928% |
| Rubicon Organics Inc. | -1.08 Million CAD | -160.307% |
| BioSyent Inc. | 7.47 Million CAD | 137.749% |
| Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | -130.991% |